Pfizer Inc. to Present Clinical Data From Its Hematology Portfolio at the 54th Annual Meeting of the American Society of Hematology

Published: Nov 29, 2012

NEW YORK--(BUSINESS WIRE)--Pfizer Oncology will present updated data in chronic myeloid leukemia (CML) for its oral Abl and Src kinase inhibitor, BOSULIF®(bosutinib),12,3,4,5recently approved by the U.S. Food and Drug Administration (FDA), and new data in acute lymphoblastic leukemia (ALL) and non-Hodgkin’s lymphoma (NHL) for inotuzumab ozogamicin,6,7a CD-22 directed antibody drug conjugate (ADC) that is currently being studied in two Phase 3 trials (INO-VATE trials),8,9at the upcoming 54th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, December 8-11. “The data being presented on Pfizer compounds at ASH provide important new insights into marketed products like BOSULIF (bosutinib), agents in late-stage clinical development like inotuzumab ozogamicin, and our robust hematology pipeline. This is a reflection of Pfizer’s strong commitment to bringing innovative therapies to patients with hematologic cancers,” said Dr. Mace Rothenberg, senior vice president of clinical development and medical affairs for Pfizer’s Oncology Business Unit.

Back to news